ChestPal™ Pro, a Bluetooth-Connected, Portable, Crackle and Wheeze Detection Innovation, Launches in the U.S. as Early Asthma and Allergy Season Looms

ChestPal™ Pro, a Bluetooth-Connected, Portable, Crackle and Wheeze Detection Innovation, Launches in the U.S. as Early Asthma and Allergy Season Looms
Preview
Source: Business Wire
ChestPal™ Pro, a Bluetooth-Connected, Portable, Crackle and Wheeze Detection Innovation, Launches in the U.S. as Early Asthma and Allergy Season Looms
Preview
Source: Business Wire
ATLANTA--(BUSINESS WIRE)--ChestPal™ Pro, the only commercially available digital stethoscope in the U.S. that’s clinically backed to detect, classify, record, and share crackles and wheezes, launches to healthcare practitioners today. No other smart stethoscope has the clinical utility of ChestPal™ Pro, with its automatic detection and classification of crackles and wheezes, including the conversion of lung sounds to visual spectrograms; accuracy and reliability across lung sound types; and easy lung sound recording, monitoring, and transmission capabilities.
The advanced generation device is designed to help clinicians arrive at a diagnosis accurately, quickly, and confidently, aiding in the timely treatment of life-threatening respiratory conditions, including pneumonia, asthma, and COPD. The tool enables lung exam sharing, making case escalation and referrals easy and convenient, especially in situations when a pulmonologist or other specialist is necessary and not located close to the patient.
“ChestPal™ Pro helps pick up lung sounds that are too subtle to hear when using a stethoscope alone,” said Dr. Emily Tuchman, MD, General Internal Medicine. “I listened to a patient’s lungs with my stethoscope and didn’t auscultate wheezing, but with ChestPalTM Pro, I picked up wheezing and could prescribe the steroids and inhaler my patient needed to improve.”
ChestPal™ Pro Aims to Help Reduce Avoidable Hospitalizations and ER Visits
“We created ChestPal™ Pro to make lung sound classification more objective and reliable for frontline healthcare professionals as part of their clinical decision-making process,” said Helena Binetskaya, Co-Founder and Chief Product Officer, ChestPal Ltd.
In fact, according to a recent Glimpse survey, a majority (60%) of healthcare practitioners say they send respiratory patients to the ER when they can’t accurately detect lung sounds, and 85% say they think a smart stethoscope that detects subtle lung sounds can play a role in reducing ER visits.
ChestPal Ltd is a MedTech company that creates medical devices and software for respiratory monitoring, classification, recording, and automatic computer analysis of lung sound recordings and spectrograms, powered by its proprietary algorithm. It’s headquartered in the U.K., with an office in Atlanta, Georgia, distributing its products to healthcare professionals through multiple partners including Henry Schein Inc. For more information, refer to www.chestpal.com
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.